Refanalin Uses, Dosage, Side Effects and more
Refanalin is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
| Attribute | Details |
|---|---|
| Trade Name | Refanalin |
| Generic | Terevalefim |
| Terevalefim Other Names | Refanalin, Terevalefim |
| Type | |
| Formula | C9H8N2S |
| Weight | Average: 176.24 Monoisotopic: 176.04081944 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How Refanalin works
Refanalin, a small molecule developed by Angion Biomedica Corp., mimics the activity of hepatocyte growth factor (HGF). Through its actions, it activates the c-Met cascade, exhibits c-Met dependence and c-Met receptor activation. As it is able to activate repair pathways, it has been tested in clinical trials for acute kidney injury and in delayed graft function. As of July 2020, Angion has announced a Phase 2 proof-of-concept trial to invesigate terevalefim on preventing and mitigating lung injury in patients with COVID-19 (NCT04459676).
